Abstract
Immunomodulation of autoimmune inflammatory diseases like rheumatoid arthritis can be achieved by anti-inflammatory T2 cytokines such as interleukin (IL)-4 administered by gene therapy. In this study we investigated the efficiency of adeno-associated viruses (AAV) vectors in collagen-induced arthritis (CIA). After injection of AAV-LacZ in the tarsus area of mice, the expression of the transgene was localized in the deep muscles cells near the bone. LacZ expression was found in liver, heart and lung after i.m. injection of AAV-LacZ, showing a spread of the vector over the body. Anti-AAV neutralizing antibodies were detected in the serum after i.m. injection of AAV-LacZ, but they did not alter the transgene expression after re-administration of AAV-LacZ. Long-term IL-4 expression persisted 129 days after intra-muscular injection of 3.7 × 1010 or 11.2 × 1010AAV-IL-4 p.p. (average 7.7 or 17.5 pg IL-4/mg proteins, respectively). More importantly, the treatment of CIA with AAV-IL-4 vector in mice produced a therapeutic benefit, since we show a diminished prevalence of the disease, a significant reduction in paw swelling, attenuated histological synovitis and a 10 days delayed onset of arthritis. This is the first evidence that AAV vector-mediated gene therapy using a T2 cytokine is efficient in an animal model of rheumatoid arthritis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Harris ED Jr . Rheumatoid arthritis. Pathophysiology and implications for therapy New Engl J Med 1990 322: 1277–1289
Breedveld FC . Future trends in the treatment of rheumatoid arthritis: cytokine targets Rheumatology 1999 38: 11–13
Arend WP, Dayer JM . Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis Arthritis Rheum 1995 38: 151–160
Maini R et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 1999 354: 1932–1939
Weinblatt ME et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate New Engl J Med 1999 340: 253–259
Joosten LA, Helsen MM, van de Loo FA, van den Berg WB . Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra Arthritis Rheum 1996 39: 797–809
Ghivizzani SC et al. Direct adenovirus-mediated gene transfer of interleukin-1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects Proc Natl Acad Sci USA 1998 95: 4613–4618
Bakker AC et al. Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee Arthritis Rheum 1997 40: 893–900
Otani K et al. Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy J Immunol 1996 156: 3558–3562
Pan RY et al. Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist Arthritis Rheum 2000 43: 289–297
Bessis N et al. The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis Eur J Immunol 2000 30: 867–875
Trentham DE, Townes AS, Kang AH . Autoimmunity to type II collagen an experimental model of arthritis J Exp Med 1977 146: 857–868
Courtenay JS et al. Immunisation against heterologous type II collagen induces arthrtis in mice Nature 1980 283: 666–668
Gracie JA et al. A proinflammatory role for IL-18 in rheumatoid arthritis J Clin Invest 1999 104: 1393–1401
Chabaud M et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium Arthritis Rheum 1999 42: 963–970
Bessis N et al. Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13 Eur J Immunol 1996 26: 2399–2403
Bessis N et al. Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13 Clin Exp Immunol 1998 111: 391–396
Chomarat P, Banchereau J, Miossec P . Differential effects of interleukins 10 and 4 on the production of interleukin-6 by blood and synovium monocytes in rheumatoid arthritis Arthritis Rheum 1995 38: 1046–1054
Mauri C, Williams RO, Walmsley M, Feldmann M . Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis Eur J Immunol 1996 26: 1511–1518
Doncarli A, Stasiuk LM, Fournier C, Abehsira-Amar O . Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis Eur J Immunol 1997 27: 1451–1458
Bessis N et al. Encapsulation in hollow fibres of xenogeneic cells engineered to secrete IL-4 or IL-13 ameliorates murine collagen-induced arthritis (CIA) Clin Exp Immunol 1999 117: 376–382
Horsfall AC et al. Suppression of collagen-induced arthritis by continuous administration of IL-4 J Immunol 1997 159: 5687–5696
Walmsley M et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis Arthritis Rheum 1996 39: 495–503
Allen JB et al. Suppression of monocyte function and differential regulation of IL-1 and IL-1ra by IL-4 contribute to resolution of experimental arthritis J Immunol 1993 151: 4344–4351
Evans CH et al. Gene therapy for rheumatic diseases Arthritis Rheum 1999 42: 1–16
Makarov SS et al. Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA Proc Natl Acad Sci USA 1996 93: 402–406
Apparailly F et al. Adenovirus mediated transfer of viral IL-10 gene inhibits collagen-induced arthritis J Immunol 1998 160: 5213–5220
Bueler H . Adeno-associated viral vectors for gene transfer and gene therapy Biol Chem 1999 380: 613–622
Chirmule N et al. Immune responses to adenovirus and adeno-associated virus in humans Gene Therapy 1999 6: 1574–1583
Lubberts E et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction J Immunol 1999 163: 4546–4556
Boyle DL et al. Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced th2 activity Gene Therapy 1999 6: 1911–1918
Whalen JD et al. Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws J Immunol 1999 162: 3625–3632
Kim KN et al. Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer J Immunol 2000 164: 1576–1581
Lechman ER et al. Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees J Immunol 1999 163: 2202–2208
Chomarat P et al. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10 J Immunol 1995 154: 1432–1439
Dechanet J, Rissoan MC, Banchereau J, Miossec P . Interleukin 4, but not interleukin 10, regulates the production of inflammation mediators by rheumatoid synoviocytes Cytokine 1995 7: 176–183
Borghaei RC, Rawlings PL Jr, Mochan E . Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts Arthritis Rheum 1998 41: 1398–1406
Colotta F et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4 Science 1993 261: 472–475
Cope AP et al. Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells Cytokine 1993 5: 205–212
Mueller R, Krahl T, Sarvetnick N . Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice J Exp Med 1996 184: 1093–1099
Shaw MK et al. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis J Exp Med 1997 185: 1711–1714
Snyder RO et al. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice Hum Gene Ther 1997 8: 1891–1900
Fisher KJ et al. Recombinant adeno-associated virus for muscle directed gene therapy Nature Med 1997 3: 306–312
During MJ et al. Peroral gene therapy of lactose intolerance using an adeno-associated virus vector Nature Med 1998 4: 1131–1135
Haberman RP, McCown TJ, Samulski RJ . Inducible long-term gene expression in brain with adeno-associated virus gene transfer Gene Therapy 1998 5: 1604–1611
Mandel RJ, Spratt SK, Snyder RO, Leff SE . Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats Proc Natl Acad Sci USA 1997 94: 14083–14088
Herzog RW et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector Nature Med 1999 5: 56–63
Zhou S, Murphy JE, Escobedo JA, Dwarki VJ . Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates Gene Therapy 1998 5: 665–670
Quattrocchi E et al. Paradoxical effects of adenovirus-mediated blockade of TNF activity in murine collagen-induced arthritis J Immunol 1999 163: 1000–1009
Goossens PH et al. Feasibility of adenovirus-mediated nonsurgical synovectomy in collagen-induced arthritis-affected rhesus monkeys Hum Gene Ther 1999 10: 1139–1149
Jorgensen C et al. Gene transfer to human rheumatoid synovial tissue engrafted in SCID mice J Rheumatol 1997 24: 2076–2079
Zhang H et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer J Clin Invest 1997 100: 1951–1957
Jooss K, Yang Y, Fisher KJ, Wilson JM . Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers J Virol 1998 72: 4212–4223
Xiao X, Li J, Samulski RJ . Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector J Virol 1996 70: 8098–8108
Halbert CL et al. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration J Virol 1997 71: 5932–5941
Brockstedt DG et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration Clin Immunol 1999 92: 67–75
Goater J et al. Empirical advantages of adeno-associated viral vectors for in vivo gene therapy for arthritis J Rheumatol 2000 27: 983–989
Ye X et al. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer Science 1999 283: 88–91
Snyder O, Xiao XP, Samulski RJ . Current protocols in human genetics. In: Dracopoli NC et al (eds) Production of Recombinant Adeno-associated Viral Vectors J Wiley: USA 1996 unit 12.1
Xiao X, Li J, Samulski RJ . Production of high-titer recombinant adeno-associated virus vectors in the absence of helperadenovirus J Virol 1998 72: 2224–2232
Braas G, Searle PF, Slater NK, Lyddiatt A . Strategies for the isolation and purification of retroviral vectors for gene therapy Bioseparation 1996 6: 211–228
Lyddiatt A, O'Sullivan DA . Biochemical recovery and purification of gene therapy vectors Curr Opin Biotechnol 1998 9: 177–185
Salvetti A et al. Factors influencing recombinant adeno-associated virus production Hum Gene Ther 1998 9: 695–706
Boissier M-C et al. Arthritogenicity of minor cartilage collagens (type IX and XI) in mice Arthritis Rheum 1990 33: 1–8
Boissier M-C et al. Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis Ann Rheum Dis 1987 46: 691–700
Manoury-Schwartz B et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors J Immunol 1997 158: 5501–5506
Acknowledgements
We would like to thank Mariane Ziol (UPRES EA-2361) for assistance with histology processing, Patrick Nicolas, Roger Vassy (UPRES EA-2360), Alexandre Megnigbeto and Christian Portafax (University of Paris XIII) for their expert advice in statistics. We are grateful to Delphine Lemeiter, Monique Etienne and Simone Beranger for their outstanding technical assistance and to Stéphane Chambris for his expert care of the animals. This work was supported by two French nonprofit organizations, the ‘Association de Recherche sur la Polyarthrite’ and the ‘Société Française de Rhumatologie’. We thank the Production Service Unit of Genethon III for providing AAV vectors in the frame of the Gene Vector Production Network (GVPN, http://www.genethon.fr/gvpn) supported by the Association Française contre les Myopathies (AFM, Evry, France).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cottard, V., Mulleman, D., Bouille, P. et al. Adeno-associated virus-mediated delivery of IL-4 prevents collagen-induced arthritis. Gene Ther 7, 1930–1939 (2000). https://doi.org/10.1038/sj.gt.3301324
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301324
Keywords
This article is cited by
-
Arthritis models: usefulness and interpretation
Seminars in Immunopathology (2017)
-
Super-resolution imaging of nuclear import of adeno-associated virus in live cells
Molecular Therapy - Methods & Clinical Development (2015)
-
Intra-articular delivery of anti-Hif-2α siRNA by chondrocyte-homing nanoparticles to prevent cartilage degeneration in arthritic mice
Gene Therapy (2015)
-
Prediction of adeno-associated virus neutralizing antibody activity for clinical application
Gene Therapy (2015)